Want to see IN:CONCORDBIO full AI Analyst Report?
Top Page
Concord Biotech Ltd.
(CONCORDBIO)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹1,407.00
▲(12.68% Upside)
Action:Upgraded
Date:08/19/26
Score is driven primarily by strong financial resilience (excellent balance sheet and solid profitability) and bullish technical trend signals. This is meaningfully offset by expensive valuation (high P/E and low yield) and some recent softening in operating momentum (2026 revenue decline and margin compression).
Positive Factors
Conservative balance sheet
The exceptionally conservative capital structure reduces financial risk and limits interest-related pressure on earnings. Minimal debt also preserves flexibility to fund capacity, research, or other strategic priorities internally while providing resilience if operating conditions weaken.
Negative Factors
2026 revenue decline
The reversal from several years of revenue expansion indicates that demand or execution momentum has become less consistent. If the decline persists, slower scale growth could limit operating leverage, reduce reinvestment capacity, and weaken the pace of earnings recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
The exceptionally conservative capital structure reduces financial risk and limits interest-related pressure on earnings. Minimal debt also preserves flexibility to fund capacity, research, or other strategic priorities internally while providing resilience if operating conditions weaken.
Read all positive factors
Concord Biotech Ltd. (CONCORDBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹130.28B
Dividend Yield0.61%
Average Volume (3M)9.59K
Price to Earnings (P/E)46.2
Beta (1Y)0.98
Revenue Growth4.02%
EPS Growth-12.81%
CountryIN
Employees1,624
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)26.24
Shares Outstanding104,616,200
10 Day Avg. Volume8,404
30 Day Avg. Volume9,590
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.19
Revenue Forecast (FY)₹12.97B
Concord Biotech Ltd. Business Overview & Revenue Model
Company Description
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients...
Concord Biotech Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
94
Very Positive
Cash Flow
73
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.08B | 10.55B | 12.00B | 10.17B | 8.53B | 7.13B |
| Gross Profit | 5.66B | 4.42B | 7.68B | 6.67B | 6.61B | 5.41B |
| EBITDA | 4.25B | 4.19B | 5.14B | 4.40B | 3.54B | 2.79B |
| Net Income | 2.75B | 2.61B | 3.72B | 3.08B | 2.40B | 1.75B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 22.35B | 20.34B | 17.01B | 15.14B | 13.13B |
| Cash, Cash Equivalents and Short-Term Investments | 4.32B | 4.16B | 3.18B | 2.86B | 1.81B | 1.62B |
| Total Debt | 0.00 | 23.16M | 29.69M | 97.38M | 315.47M | 624.93M |
| Total Liabilities | -20.15B | 2.20B | 2.22B | 1.74B | 2.24B | 2.10B |
| Stockholders Equity | 20.15B | 20.17B | 18.13B | 15.27B | 12.90B | 11.03B |
Cash Flow | ||||||
| Free Cash Flow | 975.85M | 1.74B | 1.36B | 1.80B | 1.01B | 519.70M |
| Operating Cash Flow | 1.51B | 2.69B | 2.47B | 2.65B | 2.46B | 2.07B |
| Investing Cash Flow | -212.84M | -1.45B | -1.63B | -1.55B | -1.58B | -1.12B |
| Financing Cash Flow | -1.13B | -1.13B | -986.67M | -992.15M | -852.19M | -1.00B |
Concord Biotech Ltd. Technical Analysis
Negative
1248.65
Price Trends
1419.74
Negative
1378.33
Negative
1264.06
Negative
Market Momentum
-43.83
Positive
39.91
Neutral
20.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CONCORDBIO, the sentiment is Negative. The current price of 1248.65 is below the 20-day moving average (MA) of 1321.16, below the 50-day MA of 1419.74, and below the 200-day MA of 1264.06, indicating a bearish trend. The MACD of -43.83 indicates Positive momentum. The RSI at 39.91 is Neutral, neither overbought nor oversold. The STOCH value of 20.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CONCORDBIO.
Concord Biotech Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹466.85B | 80.86 | ― | 0.24% | ― | ― | |
76 Outperform | ₹130.28B | 46.20 | ― | 0.61% | 4.02% | -12.81% | |
56 Neutral | ₹22.76B | 33.34 | ― | 0.11% | -20.86% | -34.51% | |
56 Neutral | ₹162.52B | 86.98 | ― | 0.31% | -5.99% | -60.30% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | ₹573.10B | 103.47 | ― | 0.14% | 9.83% | 5.07% | |
47 Neutral | ₹19.17B | -270.04 | ― | 0.56% | 10.26% | -162.02% |
* General Sector Average
IN:CONCORDBIO
Concord Biotech Ltd.
1,245.30
-188.76
-13.16%
IN:BIOCON
Biocon Limited
352.00
-19.56
-5.26%
IN:DCAL
Dishman Carbogen Amcis Ltd.
145.15
-146.60
-50.25%
IN:PANACEABIO
Panacea Biotec Limited
312.95
-124.80
-28.51%
IN:SYNGENE
Syngene International Ltd.
402.60
-245.86
-37.91%
IN:ANTHEM
Anthem Biosciences Limited
828.45
119.90
16.92%
Concord Biotech Ltd. Corporate Events
Concord Biotech Approves 1:1 Bonus Issue and Doubles Authorised Share Capital
Sep 23, 2026
Concord Biotech Limited’s board has approved a 1:1 bonus issue, granting shareholders one additional equity share for every fully paid-up share held as of a record date to be set later. The bonus shares will be issued by capitalizing the com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.